Literature DB >> 8877532

Characterization of an inhibitor-resistant enzyme IRT-2 derived from TEM-2 beta-lactamase produced by Proteus mirabilis strains.

L Bret1, C Chanal, D Sirot, R Labia, J Sirot.   

Abstract

Ten clinical isolates of Proteus mirabilis were found to produce an inhibitor-resistant TEM beta-lactamase (IRT) in association with a TEM-1 enzyme. The IRT enzyme was derived from TEM-2. The blaIRT gene differs from blaTEM-2 gene by one point mutation which leads to the amino-acid substitution Arg-->Ser at position 244, as observed for the original IRT-2 enzyme derived from TEM-1 reported in Escherichia coli. This is the first report of an IRT beta-lactamase derived from TEM-2.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8877532     DOI: 10.1093/jac/38.2.183

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  25 in total

1.  What's New in beta-lactamases?

Authors:  Patricia A. Bradford
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

2.  Updated sequence information and proposed nomenclature for bla(TEM) genes and their promoters.

Authors:  V Leflon-Guibout; B Heym; M Nicolas-Chanoine
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

3.  BetalasEN: microdilution panel for identifying beta-lactamases present in isolates of Enterobacteriaceae.

Authors:  Christine C Sanders; Anton F Ehrhardt; Ellen Smith Moland; Kenneth S Thomson; Barbara Zimmer; Darcie E Roe
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

4.  TEM-89 beta-lactamase produced by a Proteus mirabilis clinical isolate: new complex mutant (CMT 3) with mutations in both TEM-59 (IRT-17) and TEM-3.

Authors:  C Neuwirth; S Madec; E Siebor; A Pechinot; J M Duez; M Pruneaux; M Fouchereau-Peron; A Kazmierczak; R Labia
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

5.  Mutant TEM beta-lactamase producing resistance to ceftazidime, ampicillins, and beta-lactamase inhibitors.

Authors:  Sergei Vakulenko; Dasantila Golemi
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

Review 6.  Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.

Authors:  P A Bradford
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

7.  Quantifying nonspecific TEM beta-lactamase (blaTEM) genes in a wastewater stream.

Authors:  Karen L Lachmayr; Lee J Kerkhof; A Gregory Dirienzo; Colleen M Cavanaugh; Timothy E Ford
Journal:  Appl Environ Microbiol       Date:  2008-11-07       Impact factor: 4.792

8.  Analysis of the plasticity of location of the Arg244 positive charge within the active site of the TEM-1 beta-lactamase.

Authors:  David C Marciano; Nicholas G Brown; Timothy Palzkill
Journal:  Protein Sci       Date:  2009-10       Impact factor: 6.725

Review 9.  Catalytic properties of class A beta-lactamases: efficiency and diversity.

Authors:  A Matagne; J Lamotte-Brasseur; J M Frère
Journal:  Biochem J       Date:  1998-03-01       Impact factor: 3.857

10.  Genetic and structural characterization of an L201P global suppressor substitution in TEM-1 beta-lactamase.

Authors:  David C Marciano; Jeanine M Pennington; Xiaohu Wang; Jian Wang; Yu Chen; Veena L Thomas; Brian K Shoichet; Timothy Palzkill
Journal:  J Mol Biol       Date:  2008-09-16       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.